Page last updated: 2024-09-03

rasagiline and Amentia

rasagiline has been researched along with Amentia in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cakmur, R; Emre, M; Feyzioglu, A; Gunal, DI; Gurvit, H; Hanagasi, HA; Horozoglu, H; Sahin, HA; Tuncer, N; Unsalan, P; Yener, GG	1
Fridkin, M; Youdim, MB; Zheng, H	1
Bakhle, YS; Youdim, MB	1

Reviews

2 review(s) available for rasagiline and Amentia

Article	Year
Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mechanisms of ageing and development, 2005, Volume: 126, Issue:2 Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Brain; Chelating Agents; Cholinesterase Inhibitors; Cholinesterases; Culture Media, Serum-Free; Dementia; Dopamine; Dose-Response Relationship, Drug; Humans; Indans; Iron; Lewy Bodies; MAP Kinase Signaling System; Models, Chemical; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Neurons; Piperazines; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Quinolines	2005
Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. British journal of pharmacology, 2006, Volume: 147 Suppl 1 Topics: Animals; Cholinesterase Inhibitors; Dementia; Depressive Disorder; History, 20th Century; History, 21st Century; Humans; Indans; Iron; Iron Deficiencies; Isoenzymes; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Selegiline	2006

Article

Year

Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.

Mechanisms of ageing and development, 2005, Volume: 126, Issue:2

Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Brain; Chelating Agents; Cholinesterase Inhibitors; Cholinesterases; Culture Media, Serum-Free; Dementia; Dopamine; Dose-Response Relationship, Drug; Humans; Indans; Iron; Lewy Bodies; MAP Kinase Signaling System; Models, Chemical; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Neurons; Piperazines; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Quinolines

2005

Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.

British journal of pharmacology, 2006, Volume: 147 Suppl 1

Topics: Animals; Cholinesterase Inhibitors; Dementia; Depressive Disorder; History, 20th Century; History, 21st Century; Humans; Indans; Iron; Iron Deficiencies; Isoenzymes; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Selegiline

2006

Trials

1 trial(s) available for rasagiline and Amentia

Article	Year
The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Movement disorders : official journal of the Movement Disorder Society, 2011, Aug-15, Volume: 26, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Attention; Cognition Disorders; Dementia; Double-Blind Method; Executive Function; Female; Humans; Indans; Language; Male; Memory; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Psychiatric Status Rating Scales; Visual Perception	2011

Article

Year

The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.

Movement disorders : official journal of the Movement Disorder Society, 2011, Aug-15, Volume: 26, Issue:10

Topics: Adult; Aged; Aged, 80 and over; Attention; Cognition Disorders; Dementia; Double-Blind Method; Executive Function; Female; Humans; Indans; Language; Male; Memory; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Psychiatric Status Rating Scales; Visual Perception

2011